secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001558370-25-004746
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology
--------------------------------------------------------------------------------

- Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.
- Eligible for two milestone payments up to $75M total if net sales thresholds met through 2027.
- Pro forma cash balance post-close ~$250M; cash runway extended over two years into 2027.
- Plans to use proceeds to repurchase $230M of 1.500% Convertible Notes due 2026.
- Focus shifts to LOQTORZI, casdozokitug, and CHS-114 novel oncology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/0001558370-25-004746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/chrs-20250411x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer